Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR-12286 Dose-Response in Glaucoma and Ocular Hypertension
NCT00902200Phase 2Completed
- Sponsor
- Aerie Pharmaceuticals
- Start
- May 2009
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of verosudil in open-angle glaucoma (OAG), ocular hypertension, sponsored by Aerie Pharmaceuticals. Started May 2009; status: completed.
02
Drugs
verosudil
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT00902200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00902200.